enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report)'s share price gapped up prior to trading on Thursday . The stock had previously closed at $13.62, but opened at $13.96. enGene shares last traded at $13.96, with a volume of 241 shares changing hands.
Analysts Set New Price Targets
Several research firms have weighed in on ENGN. UBS Group initiated coverage on shares of enGene in a research report on Thursday, March 28th. They set a "buy" rating and a $37.00 target price on the stock. Leerink Partnrs reissued an "outperform" rating on shares of enGene in a research report on Tuesday, February 20th. Wells Fargo & Company initiated coverage on enGene in a research report on Monday, April 22nd. They set an "overweight" rating and a $30.00 price target for the company. Guggenheim assumed coverage on enGene in a report on Monday, April 15th. They issued a "buy" rating and a $34.00 price objective on the stock. Finally, SVB Leerink began coverage on enGene in a report on Tuesday, February 20th. They set an "outperform" rating and a $31.00 target price for the company. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $34.40.
Check Out Our Latest Stock Report on ENGN
enGene Stock Up 4.2 %
The firm's 50 day moving average price is $16.01.
Insider Buying and Selling
In other enGene news, major shareholder De Solidarite Des Travai Fonds sold 47,854 shares of the business's stock in a transaction that occurred on Monday, April 22nd. The stock was sold at an average price of $15.00, for a total value of $717,810.00. Following the completion of the transaction, the insider now directly owns 3,036,153 shares of the company's stock, valued at $45,542,295. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 13.70% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Altitude Crest Partners Inc. acquired a new stake in shares of enGene during the 1st quarter valued at about $2,039,000. Vivo Capital LLC acquired a new stake in enGene in the fourth quarter valued at approximately $6,264,000. Janus Henderson Group PLC purchased a new stake in shares of enGene in the first quarter valued at approximately $17,095,000. Omega Fund Management LLC acquired a new position in shares of enGene during the 4th quarter worth approximately $10,441,000. Finally, BVF Inc. IL purchased a new position in shares of enGene during the 4th quarter valued at approximately $20,777,000. Hedge funds and other institutional investors own 64.16% of the company's stock.
About enGene
(
Get Free Report)
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider enGene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and enGene wasn't on the list.
While enGene currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
